Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 135

Similar articles for PubMed (Select 22694113)

1.

Cost-effectiveness analysis of SBRT versus IMRT: an emerging initial radiation treatment option for organ-confined prostate cancer.

Hodges JC, Lotan Y, Boike TP, Benton R, Barrier A, Timmerman RD.

Am J Manag Care. 2012 May 1;18(5):e186-93.

2.

(S044) Patient-Reported Quality of Life After Stereotactic Body Radiotherapy (SBRT), Intensity-Modulated Radiotherapy (IMRT), and Brachytherapy.

[No authors listed]

Oncology (Williston Park). 2015 Apr 21;29(4 Suppl 1). pii: 204977. No abstract available.

3.

(S013) Heterogeneity Within the Prostate and Risk-Adapting Dose-Volume Analysis With SBRT for Prostate Cancer.

[No authors listed]

Oncology (Williston Park). 2015 Apr 21;29(4 Suppl 1). pii: 204971. No abstract available.

4.

Dose-Escalated Robotic SBRT for Stage I-II Prostate Cancer.

Meier R.

Front Oncol. 2015 Apr 7;5:48. doi: 10.3389/fonc.2015.00048. eCollection 2015. Review.

5.

Stereotactic body radiotherapy for prostate cancer.

Henderson DR, Tree AC, van As NJ.

Clin Oncol (R Coll Radiol). 2015 May;27(5):270-9. doi: 10.1016/j.clon.2015.01.011. Epub 2015 Feb 21.

PMID:
25707911
6.

Cost-effectiveness analysis of single fraction of stereotactic body radiation therapy compared with single fraction of external beam radiation therapy for palliation of vertebral bone metastases.

Kim H, Rajagopalan MS, Beriwal S, Huq MS, Smith KJ.

Int J Radiat Oncol Biol Phys. 2015 Mar 1;91(3):556-63. doi: 10.1016/j.ijrobp.2014.10.055. Epub 2015 Jan 30.

PMID:
25680599
7.

Comparing outcomes of stereotactic body radiotherapy with intensity-modulated radiotherapy for patients with locally advanced unresectable pancreatic cancer.

Lin JC, Jen YM, Li MH, Chao HL, Tsai JT.

Eur J Gastroenterol Hepatol. 2015 Mar;27(3):259-64. doi: 10.1097/MEG.0000000000000283.

PMID:
25629569
8.

Spacers in radiotherapy treatment of prostate cancer: is reduction of toxicity cost-effective?

Vanneste BG, Pijls-Johannesma M, Van De Voorde L, van Lin EN, van de Beek K, van Loon J, Ramaekers BL, Lambin P.

Radiother Oncol. 2015 Feb;114(2):276-81. doi: 10.1016/j.radonc.2015.01.005. Epub 2015 Jan 20.

9.

Toxicity and cost-effectiveness analysis of intensity modulated radiation therapy versus 3-dimensional conformal radiation therapy for postoperative treatment of gynecologic cancers.

Chen LA, Kim J, Boucher K, Terakedis B, Williams B, Nickman NA, Gaffney DK.

Gynecol Oncol. 2015 Mar;136(3):521-8. doi: 10.1016/j.ygyno.2014.12.039. Epub 2015 Jan 3.

PMID:
25562668
10.

Cost of selective internal radiation therapy versus other modalities.

Wasan HS.

Future Oncol. 2014 Nov;10(15 Suppl):101-4. doi: 10.2217/fon.14.235. No abstract available.

PMID:
25478779
11.

Stereotactic body radiation therapy for prostate cancer: Rational and reasonable.

Kupelian P, Mehta NH, King C, Steinberg M, Finkelstein SE, Fernandez E.

Pract Radiat Oncol. 2015 May-Jun;5(3):188-92. doi: 10.1016/j.prro.2014.08.018. Epub 2014 Oct 18.

PMID:
25413392
12.

Bending the cost curve: a unique collaboration between radiation oncologists and Blue Cross Blue Shield of Massachusetts to optimize the use of advanced technology.

Steingisser L, Acker B, Berman S, Brenner MJ, Bornstein BA, Busse P, FitzGerald TJ, Jacobson JO, Jekowsky E, Kachnic LA, Mamon H, McKee A, Shulman LN, Stevenson MA, Wazer D, Fallon JA.

J Oncol Pract. 2014 Sep;10(5):e321-7. doi: 10.1200/JOP.2014.001473.

13.

Stereotactic body radiation therapy is a cost-effective alternative to intensity-modulated radiation therapy.

Quan K, Rajagopalan MS, Heron DE.

J Clin Oncol. 2014 Oct 20;32(30):3451. doi: 10.1200/JCO.2014.56.6737. Epub 2014 Sep 2. No abstract available.

PMID:
25185091
14.

Toxicity of stereotactic body radiation therapy versus intensity-modulated radiation therapy for prostate cancer: a potential comparison bias.

Arcangeli S, De Bari B, Alongi F.

J Clin Oncol. 2014 Oct 20;32(30):3454. doi: 10.1200/JCO.2014.56.3213. Epub 2014 Sep 2. No abstract available.

PMID:
25185086
15.

A framework to evaluate the cost-effectiveness of the NADiA ProsVue slope to guide adjuvant radiotherapy among men with high-risk characteristics following prostatectomy for prostate cancer.

Reed SD, Stewart SB, Scales CD Jr, Moul JW.

Value Health. 2014 Jul;17(5):545-54. doi: 10.1016/j.jval.2014.04.010. Epub 2014 Jun 3.

PMID:
25128047
16.

Systematic review of the cost effectiveness of radiation therapy for prostate cancer from 2003 to 2013.

Amin NP, Sher DJ, Konski AA.

Appl Health Econ Health Policy. 2014 Aug;12(4):391-408. doi: 10.1007/s40258-014-0106-9. Review.

PMID:
25022451
17.

Cost-effectiveness in radiation oncology: an uncomfortable but necessary question.

Paravati AJ, Murphy JD.

Int J Radiat Oncol Biol Phys. 2014 Jul 15;89(4):784-5. doi: 10.1016/j.ijrobp.2014.04.040. No abstract available.

PMID:
24969792
18.

A decision model to estimate the cost-effectiveness of intensity modulated radiation therapy (IMRT) compared to three dimensional conformal radiation therapy (3DCRT) in patients receiving radiotherapy to the prostate bed.

Carter HE, Martin A, Schofield D, Duchesne G, Haworth A, Hornby C, Sidhom M, Jackson M.

Radiother Oncol. 2014 Aug;112(2):187-93. doi: 10.1016/j.radonc.2014.03.020. Epub 2014 Jun 11.

PMID:
24929702
19.

The Technique, Resources and Costs of Stereotactic Body Radiotherapy of Prostate Cancer: A Comparison of Dose Regimens and Delivery Systems.

Sharieff W, Greenspoon JN, Dayes I, Chow T, Wright J, Lukka H.

Technol Cancer Res Treat. 2014 Apr 16. [Epub ahead of print]

PMID:
24750007
20.

Cost-effectiveness analysis of intensity modulated radiation therapy versus 3-dimensional conformal radiation therapy for anal cancer.

Hodges JC, Beg MS, Das P, Meyer J.

Int J Radiat Oncol Biol Phys. 2014 Jul 15;89(4):773-83. doi: 10.1016/j.ijrobp.2014.02.012. Epub 2014 Apr 9.

PMID:
24726392
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk